Onconetix CEO Neil Campbell resigns; interim CEO and Lead Independent Director appointed

Onconetix, Inc.

Dr. Neil Campbell resigned as President, CEO, and board member effective Jan 10, 2024; no disagreement cited.
Campbell receives $158,333 severance payment under a release of claims filed as Exhibit 99.1.
Dr. Ralph Schiess, Chief Science Officer, appointed Interim CEO effective Jan 12, 2024.
James Sapirstein named Lead Independent Director; will receive $40,000 per month for that role.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Neil Campbell

President and Chief Executive Officer

ONCO · Onconetix, Inc.

Effective: 2024-01-10
Successor: Dr. Ralph Schiess
Filed: January 12, 2024, 6:59 PM ET

Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).

Appointed

James Sapirstein

Lead Independent Director

ONCO · Onconetix, Inc.

Effective: 2024-01-12
Filed: January 12, 2024, 6:59 PM ET

Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board’s appointment of a permanent chief executive officer.

Appointed (interim)

Dr. Ralph Schiess

Interim Chief Executive Officer

ONCO · Onconetix, Inc.

Effective: 2024-01-12
Filed: January 12, 2024, 6:59 PM ET

On January 12, 2024, the Board appointed Dr. Ralph Schiess, the Company’s Chief Science Officer, to serve as the Company’s Interim Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Neil Campbell resigned as President and Chief Executive Officer at Onconetix, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

James Sapirstein was appointed as Lead Independent Director at Onconetix, Inc..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board’s appointment of a permanent chief executive officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Ralph Schiess was appointed as Interim Chief Executive Officer at Onconetix, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

On January 12, 2024, the Board appointed Dr. Ralph Schiess, the Company’s Chief Science Officer, to serve as the Company’s Interim Chief Executive Officer.

View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-003413

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.